Myriad Genetics, Inc. (MYGN) compared with its closest peers (NEOG, QDEL, CAI, LMRI, GH). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Neogen and QuidelOrtho share Myriad Genetics's sub-industry, diagnostics makers.
| Company | Market Cap | P/E |
|---|---|---|
| Neogen Corporation (NEOG) | $2.57B | -224.1 |
| QuidelOrtho Corporation (QDEL) | $956.28M | -1.8 |
| Caris Life Sciences, Inc. (CAI) | $7.01B | 66.6 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.13B | 656.4 |
| Guardant Health, Inc. (GH) | $21.88B | -30.8 |
| Sotera Health Company (SHC) | $5.41B | 33.1 |
| Veracyte, Inc. (VCYT) | $3.59B | 31.3 |
| CareDx, Inc (CDNA) | $2.57B | 23.1 |
| Castle Biosciences, Inc. (CSTL) | $1.02B | -46.9 |
| RadNet, Inc. (RDNT) | $5.96B | -285.0 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
MYGN overview · MYGN earnings · MYGN financials · MYGN KPIs · MYGN documents · MYGN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.